Primary Pancreatic Lymphoma: Endosonography-Guided Tissue Acquisition Diagnosis.
| Autor: | Orsini-Arman AC; Internal Medicine, Pontifical Catholic University of Campinas, Campinas, BRA., Surjan RCT; Surgery Department, University of São Paulo, São Paulo, BRA.; Surgery Department, Dasa/Hospital Nove de Julho, São Paulo, BRA., Venco FE; Pathology Department, Hospital Moriah, São Paulo, BRA., Ardengh JC; Gastrointestinal Endoscopy Department, Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto, BRA.; Imaging Diagnostic Department, Universidade Federal de Sao Paulo, São Paulo, BRA.; Digestive Endoscopy Department, Hospital Moriah, São Paulo, BRA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Feb 13; Vol. 15 (2), pp. e34936. Date of Electronic Publication: 2023 Feb 13 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.34936 |
| Abstrakt: | Primary pancreatic lymphoma is a rare type of cancer, that accounts for 0.1-0.5% of lymphomas and about 0.2% of all primary pancreatic tumors. Diffuse Large B-cell Lymphoma is the most common subtype. The diagnosis is possible if the lymphoma is located in the pancreas, but the differential diagnosis with pancreatic ductal adenocarcinoma is difficult. The diagnostic accuracy of endosonography-guided fine needle aspiration is inadequate, and thus it is common to diagnose these masses only after surgical resection. The endosonography-guided tissue acquisition allows greater accuracy in the pancreatic masses, as it determines optimal access to histological analysis using tissue in paraffin blocks for complementary immunohistochemical, and molecular tests. Thus, this elaborate diagnostic environment allows the adoption of appropriate treatment strategies for patients with this condition. The authors describe four cases of primary pancreatic lymphoma indicated for surgical resection due to suspected pancreatic cancer, with the diagnosis of Diffuse Large B-cell Lymphoma obtained by endosonography-guided tissue acquisition, changing the therapeutic strategy through the adoption of adequate chemotherapy treatment with good progress. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Orsini-Arman et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|